The V89L Polymorphism in the 5-α-Reductase Type 2 Gene and Risk of Breast Cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 11 II, 2003, Pages 1194-1199

  Van Gils, Carla H ^a   Onland Moret, N Charlotte ^a   Roest, Mark ^a   Van Noord, Paulus A H ^a   Peeters, Petra H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DNA; LEUCINE; STEROID 5ALPHA REDUCTASE; VALINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CODON; COHORT ANALYSIS; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RISK; RISK FACTOR; SRD5A2 GENE; SURVIVAL;

AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, GENETIC; PROGNOSIS; RANDOM ALLOCATION; RISK FACTORS; SURVIVAL ANALYSIS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0345492002     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Berrino, F., Muti, P., Micheli, A., Bolelli, G., Krogh, V., Sciajno, R., Pisani, P., Panico, S., and Secreto, G. Serum sex hormone levels after menopause and subsequent breast cancer. J. Natl. Cancer Inst. (Bethesda), 88: 291-296, 1996.
2. Dorgan, J. F., Stanczyk, F. Z., Longcope, C., Stephenson, H. E., Jr., Chang, L., Miller, R., Franz, C., Falk, R. T., and Kahle, L. Relationship of serum dehydro-epiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 β, 17 β-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol. Biomark. Prev., 6: 177-181, 1997.
3. Thomas, H. V., Key, T. J., Allen, D. S., Moore, J. W., Dowsett, M., Fentiman, I. S., and Wang, D. Y. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br. J. Cancer, 76: 401-405, 1997.
4. Zeleniuch-Jacquotte, A., Bruning, P. F., Bonfrer, J. M., Koenig, K. L., Shore, R. E., Kim, M. Y., Pasternack, B. S., and Toniolo, P. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am. J. Epidemiol., 145: 1030-1038, 1997.
5. Hankinson, S. E., Willett, W. C., Manson, J. E., Colditz, G. A., Hunter, D. J., Spiegelman, D., Barbieri, R. L., and Speizer, F. E. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. (Bethesda), 90: 1292-1299, 1998.
6. Cauley, J. A., Lucas, F. L., Kuller, L. H., Stone, K., Browner, W., and Cummings, S. R. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med., 130: 270-277, 1999.
7. Wang, D. Y., Allen, D. S., De Stavola, B. L., Fentiman, I. S., Brussen, J., Bulbrook, R. D., Thomas, B. S., Hayward, J. L., and Reed, M. J. Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey. Br. J. Cancer, 82: 1577-1584, 2000.
8. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. (Bethesda), 94: 606-616, 2002.
9. Onland-Moret, N. C., Kaaks, R., van Noord, P. A., Rinaldi, S., Key, T., Grobbee, D. E., and Peeters, P. H. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br. J. Cancer, 88: 1394-1399, 2003.
10. Santner, S. J., Chen, S., Zhou, D., Korsunsky, Z., Martel, J., and Santen, R. J. Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture. J. Steroid. Biochem. Mol. Biol., 44: 611-616, 1993.
11. Schmitt, M., Klinga, K., Schnarr, B., Morfin, R., and Mayer, D. Dehydro-epiandrosterone stimulates proliferation and gene expression in MCF-7 cells after conversion to estradiol. Mol. Cell. Endocrinol., 173: 1-13, 2001.
12. Lippman, M., Bolan, G., and Huff, K. The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res., 36: 4610-4618, 1976.
13. Baratta, M., Grolli, S., Poletti, A., Ramoni, R., Motta, M., and Tamanini, C. Role of androgens in proliferation and differentiation of mouse mammary epithelial cell line HC11. J. Endocrinol., 167: 53-60, 2000.
14. Labrie, F., Sugimoto, Y., Luu-The, V., Simard, J., Lachance, Y., Bachvarov, D., Leblanc, G., Durocher, F., and Paquet, N. Structure of human type II 5 α-reductase gene. Endocrinology, 131: 1571-1573, 1992.
15. Maggiolini, M., Donze, O., Jeannin, E., Ando, S., and Picard, D. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α. Cancer Res., 59: 4864-4869, 1999.
16. Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., and Russell, D. W. Tissue distribution and ontogeny of steroid 5 α-reductase isozyme expression. J. Clin. Investig., 92: 903-910, 1993.
17. Suzuki, T., Darnel, A. D., Akahira, J. I., Ariga, N., Ogawa, S., Kaneko, C., Takeyama, J., Moriya, T., and Sasano, H. 5α-Reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J. Clin. Endocrinol. Metab., 86: 2250-2257, 2001.
18. Wiebe, J. P., Muzia, D., Hu, J., Szwajcer, D., Hill, S. A., and Seachrist, J. L. The 4-pregnene and 5α-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res., 60: 936-943, 2000.
19. Perel, E., Daniilescu, D., Kharlip, L., Blackstein, M. E., and Killinger, D. W. The relationship between growth and androstenedione metabolism in four cell lines of human breast carcinoma cells in culture. Mol. Cell. Endocrinol., 41: 197-203, 1985.
20. Makridakis, N. M., di Salle, E., and Reichardt, J. K. Biochemical and pharmacogenetic dissection of human steroid 5 α-reductase type II. Pharmacogenetics, 10: 407-413, 2000.
21. Makridakis, N., Ross, R. K., Pike, M. C., Chang, L., Stanczyk, F. Z., Kolonel, L. N., Shi, C. Y., Yu, M. C., Henderson, B. E., and Reichardt, J. K. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res., 57: 1020-1022, 1997.
22. Makridakis, N. M., Ross, R. K., Pike, M. C., Crocitto, L. E., Kolonel, L. N., Pearce, C. L., Henderson, B. E., and Reichardt, J. K. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet, 354: 975-978, 1999.
23. Febbo, P. G., Kantoff, P. W., Platz, E. A., Casey, D., Batter, S., Giovannucci, E., Hennekens, C. H., and Stampfer, M. J. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res., 59: 5878-5881, 1999.
24. Lunn, R. M., Bell, D. A., Mohler, J. L., and Taylor, J. A. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis (Lond.), 20: 1727-1731, 1999.
25. Yang, C., Hamajima, N., Iwata, H., Saito, T., Matsuo, K., Hirose, K., Inoue, M., Takezaki, T., and Tajima, K. A49T, V89L and TA repeat polymorphisms of steroid 5-α-reductase type II and breast cancer risk in Japanese women. Breast Cancer Res., 4: R8, 2002.
26. Scorilas, A., Bharaj, B., Giai, M., and Diamandis, E. P. Codon 89 polymorphism in the human 5 α-reductase gene in primary breast cancer. Br. J. Cancer, 84: 760-767, 2001.
27. De Waard, F., Collette, H. J. A., Rombach, J. J., Baanders-van Halewijn, E. A., and Honing, C. The DOM-project for early diagnosis of breast cancer. J. Chron. Dis., 47: 41-44, 1984.
28. Bureau voor Statistiek Utrecht. De bevolking van Utrecht per 1 januari 1979. Utrecht, 1979.
29. Bestuursinformatie. Bevolking van Utrecht per 1 januari 1994. Utrecht, Gemeente Utrecht, 1994.
30. Van der Hel, O. L., Van der Luijt, R. B., Bas Bueno, d. M., van Noord, P. A., Slothouber, B., Roest, M., Van der Schouw, Y. T., Grobbee, D. E., Pearson, P. L., and Peeters, P. H. Quality and quantity of DNA isolated from frozen urine in population-based research. Anal. Biochem., 304: 206-211, 2002.
31. Roest, M., Van der Schouw, Y. T., De Valk, B., Marx, J. J., Tempelman, M. J., De Groot, P. H., Sixma, J. J., and Banga, J. D. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation, 100: 1268-1273, 1999.
32. Saiki, R. K., Bugawan, T. L., Horn, G. T., Mullis, K. B., and Erlich, H. A. Analysis of enzymatically amplified β-globin and HLA-DQ α DNA with allele-specific oligonucleotide probes. Nature (Lond.), 324: 163-166, 1986.
33. DeMarchi, J. M., Richards, C. S., Fenwick, R. G., Pace, R., and Beaudet, A. L. A robotics-assisted procedure for large scale cystic fibrosis mutation analysis. Hum. Mutat., 4: 281-290, 1994.
34. Hezard, N., Cornillet-Lefebvre, P., Gillot, L., Potron, G., and Nguyen, P. Multiplex ASA PCR for a simultaneous determination of factor V Leiden gene, G→A 20210 prothrombin gene and C→T 677 MTHFR gene mutations. Thromb. Haemost., 79: 1054-1055, 1998.
35. Labuda, D., Krajinovic, M., Richer, C., Skoll, A., Sinnett, H., Yotova, V., and Sinnett, D. Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. Anal. Biochem., 275: 84-92, 1999.
36. Barlow, W. E., Ichikawa, L., Rosner, D., and Izumi, S. Analyses of case-cohort designs. J. Clin. Epidemiol., 52: 1165-1172, 1999.
37. Bharaj, B., Scorilas, A., Giai, M., and Diamandis, E. P. TA repeat polymorphism of the 5α-reductase gene and breast cancer. Cancer Epidemiol. Biomark. Prev., 9: 387-393, 2000.
38. Spurdle, A. B., Hopper, J. L., Chen, X., Dite, G. S., McCredie, M. R., Giles, G. G., Venter, D. J., Southey, M. C., Purdie, D. M., and Chenevix-Trench, G. The steroid 5α-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women. Cancer Epidemiol. Biomark. Prev., 10: 1287-1293, 2001.